4.3 Article

miRNA-223 suppresses FOX01 and functions as a potential tumor marker in breast cancer

期刊

CELLULAR AND MOLECULAR BIOLOGY
卷 63, 期 5, 页码 113-118

出版社

C M B ASSOC
DOI: 10.14715/cmb/2017.63.5.21

关键词

Breast Cancer; microRNA; FOX01; Cell proliferation

向作者/读者索取更多资源

Breast cancer is the most commonly diagnosed cancer in women and a leading cause of cancer mortality. MicroRNAs (miRNAs) have been found to play a key role in proliferation, metastasis and invasion of cancer. In previous study, we found that miRNA-223 was significant expression inexosome derived from peripheral blood serum of breast cancer patients than in samples from control subjects, Thereforthe role ofmiRNA-223willbe researched in MCF-7 breast cancer cells.In this study, to explore the role of miRNA-223in influencing cell proliferation, metastasis and invasion abreast cancer, TargetScan tools (http://www.targetscamorg/vert71/) was used to scan target genes of miRNA-223, and thenmiRNA expression, real time PCR, Western blotting andluciferase report assay were used to test regulates relationship of miRNA-223and its targets,cell viability and BrdI; analysiswere used to test cell proliferation of MCF-7 breast cancer cells after expression miRNA-223inhibitor. Scanning targets of miRNA-223found FOX01 was listed in targets content, and luciferase reporter assay was used to assess and confirm the binding sequence of 3`untranslated region between FOX01 and miRNA-223. Results showedthat miRNA-223inhibitorexpression increased protein expression level of FOX01 in MCF-7 breast cancer cells,meanwhile, cell viability and BrdI T analysis showed MCF-7 breast cancer cells were suppressed proliferation after up-regulation of FOX01.In conclusion, we demonstrated that the miRNA-223can maintain cell proliferation of breast cancer cell through targeting FOX I, these results provide a new insight in tumor marker and potential therapeutic targets for breast cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据